Gastroenterology: Scientists may be able to predict whether colorectal cancer will respond to immunotherapy!

June 30, 2021/Bio Valley BIOON/ - Colorectal cancer responds differently to immune checkpoint blocking therapies, and this may be partly due to the high tumor mutation burden (TMB)

Image source: https://#%20

Colorectal cancer is commonly known as bowel cancer, which is cancer that occurs in the colon or rectum.

In the article, the researchers selected more than 700 cancer tissue samples and surrounding non-cancerous cell samples from 29 patients receiving immune checkpoint blocking therapy for research (this research is part of the international clinical trial research).

Researchers have found that there are many factors that affect whether immunotherapy can effectively treat patients

High-resolution imaging of colorectal cancer reveals the CD74+ macrophage population (background image), CD8+GzB+ and CD8+Ki67+ T cell interaction maps (enlarged image)

Image source: Michele Bortolomeazzi, et al.

Researcher Francesca said that the results of this article will help clinicians to screen out patients who can respond to immune checkpoint inhibitors before giving them treatment, so as to maximize the benefits of treatment; and this is what researchers currently want to solve The problem provides new opportunities.

In summary, this study clarifies the limitations of TMB as a predictor of colorectal cancer response to anti-PD1 immunotherapy.

Original source:

Michele Bortolomeazzi, Mohamed Reda Keddar, Lucia Montorsi, et al.